Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

432
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
432
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

591
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
591
Pulse rhythm01:30

Pulse rhythm

803
Pulse rhythm refers to the pattern of pulsations within specific intervals, offering valuable insights into the regularity or irregularity of the heart's beats as observed through the pattern of pulsation within specific intervals. A regular pulse exhibits a consistent heart rate with uniform waveforms and pulsation force, variations of which can be classified as normal, weak, or bounding.
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac...
803
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

341
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
341
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

384
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
384

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Circulating metabolomic and lipidomic profiles distinguish patients with acute heart failure de novo vs. worsening of heart failure.

Polish archives of internal medicine·2026
Same author

Worsening renal function in acute heart failure: a hemoconcentration-conditioned interpretation with ranges of benefit, safety, and harm.

Revista espanola de cardiologia (English ed.)·2026
Same author

A Machine-Learning Model for Accurate Diuresis Prediction in Acute Heart Failure (DRC-AHF).

ESC heart failure·2026
Same author

A Contemporary Perspective on Acute Decompensated Heart Failure Classification: A State-of-the-art Review from an International Expert Group.

Cardiac failure review·2026
Same author

Acute Myocardial Infarction versus Acute Decompensated Heart Failure in Cardiogenic Shock: A Systematic Review and Meta-Analysis of Clinical Phenotypes and Mortality.

European journal of heart failure·2026
Same author

Contemporary Management of Acute Heart Failure: From Emergency Presentation to Long-Term Remission.

Journal of the American College of Cardiology·2026

Related Experiment Video

Updated: Jul 5, 2025

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

793

Emerging devices for heart failure management.

Fouad Chouairi1, Allison Levin2, Jan Biegus3

  • 1Department of Medicine, Duke University School of Medicine, Durham, NC, USA.

Progress in Cardiovascular Diseases
|January 19, 2024
PubMed
Summary
This summary is machine-generated.

Recent advances in heart failure (HF) treatment include guideline-directed medical therapy (GDMT) and novel device therapies. This review highlights emerging devices for HF management, crucial for cardiologists to understand.

Keywords:
DevicesHFpEFHeart failureRemote monitoring

More Related Videos

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.5K
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.3K

Related Experiment Videos

Last Updated: Jul 5, 2025

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

793
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.5K
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.3K

Area of Science:

  • Cardiology
  • Biomedical Engineering
  • Medical Devices

Background:

  • Heart failure (HF) remains a significant cause of morbidity and mortality despite advances in guideline-directed medical therapy (GDMT).
  • Optimal medical therapy is often not achieved in many HF patients.
  • Emerging device therapies offer new avenues for HF treatment.

Purpose of the Study:

  • To review and highlight novel and emerging device therapies for heart failure (HF).
  • To familiarize cardiologists with the latest technological advancements in HF management.

Main Methods:

  • Literature review of recent advancements in HF device therapies.
  • Categorization of devices based on their mechanism of action (e.g., remote monitoring, autonomic nervous system modulation, structural heart modification).

Main Results:

  • Significant progress has been made in developing devices for remote HF monitoring.
  • Devices targeting autonomic nervous system modulation are showing promise.
  • Innovations in structural cardiac devices aim to address underlying HF pathophysiology.

Conclusions:

  • Novel device therapies are increasingly complementing GDMT in HF care.
  • Familiarity with these emerging technologies is essential for modern cardiology practice.
  • These devices represent a critical step towards addressing the root causes of HF physiology.